Results 201 to 210 of about 864,749 (292)

Bioinformatics-driven design and protective efficacy assessment of a multi-epitope vaccine for <i>Toxoplasma gondii</i>. [PDF]

Front Immunol
Feng W, Sun L, Yang C, Cao J, Zhou Y, Zhou J, Yu L, Zhang H.   +7 more
europepmc   +1 more source

Extracellular Vesicles‐Based Biological Macromolecule Delivery Systems: Biogenesis, Characterization, and Emerging Clinical Applications

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Extracellular vesicles (EVs) are nanoscale membrane‐bound structures that play a pivotal role in intercellular communication by transporting bioactive molecules, including proteins, lipids, nucleic acids, and organelles, between cells. Originating from the endosomal pathway, EVs reflect the physiological and pathological status of their parent
Emine İncilay Torunoğlu, Zeynep Betül Sarı, Muhammed Emin Sarı, Erdi Can Aytar   +3 more
wiley   +1 more source

Synthetic consensus DNA vaccines against Merkel cell polyomavirus large and small T antigens induce robust polyfunctional T cell responses. [PDF]

Front Immunol
Bhojnagarwala PS, Duperret EK, Trautz A, Weiner DB.   +3 more
europepmc   +1 more source

Purification of Disassembled Capsid Protein by Hydroxyapatite Chromatography Enhances Virus‐Like Particle Recovery

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Virus‐like particles (VLPs) are a promising modality with extensive applications in prophylactic and therapeutic vaccine design. Human Papillomavirus (HPV) vaccines are one such example where VLP vaccine applications have led to the successful reduction in HPV‐associated diseases, such as cervical cancer.
Nicholas Samuelson, Nathaniel Parker, Shiyi Wang, Sara Daley, Aaron Cote, Michael A. Winters   +5 more
wiley   +1 more source

Development and Epitope Characterization of Monoclonal Antibodies Targeting the Rabies Virus P Protein. [PDF]

J Med Virol
Liang C, Chen Y, Liu H, Zhou J, Chen Y, Qi Y, Zhu X, Liu E, Wu S, Wang A.   +9 more
europepmc   +1 more source

Characterization of Immune Responses to RBD‐SD1 Nanoparticle Vaccines Derived From ACE2‐Capable HKU5‐CoV‐2, NeoCoV, and HKU5 Merbecoviruses

Biotechnology and Bioengineering, EarlyView.
SpyCatcher‐mi3 nanoparticles presenting HKU5, NeoCoV, and HKU5‐CoV‐2 RBD‐SD1 induced strong, cross‐reactive IgG responses in immunized mice. The surrogate virus neutralization test demonstrated strong activity in sera from homologous vaccination. ABSTRACT Recent discoveries of merbecoviruses such as HKU5, NeoCoV, and HKU5‐CoV‐2 that use angiotensin ...
Peter J. Halfmann, Jeong Soo Lee, Augustine Duffy, Tong Wang, Bingcheng Huang, James Z. Kurdi, Ajay Inampudi, Natasha Chen, Elizabeth Frimpong, Carmen Rai, Yoshihiro Kawaoka, Ravi S. Kane   +11 more
wiley   +1 more source

Challenges in Defining Severe Influenza With Implications for Measuring and Communicating Influenza Vaccine Effects. [PDF]

Clin Infect Dis
Bozio CH, Patel M, Reed C, Garg S.
europepmc   +1 more source

Mechanistic Digital Model for Real‐Time Monitoring and Optimization of Adenovirus Production

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Adenoviral vectors are a critical vaccine platform, with billions of vaccine doses administered during the COVID‐19 pandemic. In addition, they are promising therapeutics for cancer treatment. To advance their manufacturing, real‐time monitoring of adenovirus production is essential for process optimization, yield improvement, and product ...
Xingge Xu, Daniel Rüdiger, Jeongbin Shin, Shawninder Chahal, Amine Kamen   +4 more
wiley   +1 more source

Reactogenicity and Immunogenicity of Adjuvanted and Nonadjuvanted RSV Vaccines in Solid Organ Transplant Recipients. [PDF]

Transplant Direct
Hannaford A, Chamberlin E, Swank Z, van Haren SD, Han S, Thomas S, Ryff K, Connolly EM, Woehl EN, Regan DJ, Valentine GC, Morreale N, Li X, Eustace A, Tong A, Lan Z, Walt DR, Levy O, Issa NC, Sharma NS, Mehra MR, Givertz MM, Tullius SG, Azzi JR, Coppolino A, Baden LR, Sherman AC, Woolley AE.   +27 more
europepmc   +1 more source

Cryo‐EM Analysis of Adenovirus Vector Reveals Purification Conditions Leading to Loss of Viral Fiber Proteins and Reduced Infectivity

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Vaccines and gene therapies require efficient delivery of genetic material to host cells. Viral vectors leverage viruses' ability to enter host cells to achieve this. Following the SARS‐CoV‐2 vaccine and novel gene therapies that utilize adenovirus vectors, there has been an increase in the demand for large‐scale production of vectors.
Betsy Widdicombe, Joseph D. Barritt, Nichakorn Pipatpadungsin, Braulio Carrillo Sanchez, Dale Stibbs, Lisa Cooper, Sarah L. Rouse, Daniel G. Bracewell   +7 more
wiley   +1 more source